31-45 of 72
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Ignacio Duran, MD
Sandy Srinivas, MD
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Ignacio Duran, MD
Sandy Srinivas, MD
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Wenxin Xu, MD
Sandy Srinivas, MD
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Wenxin Xu, MD
Sandy Srinivas, MD
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Wenxin Xu, MD
Sandy Srinivas, MD
- advertisement
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Ignacio Duran, MD
Wenxin Xu, MD
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®Emerging targeted therapy combination strategies in genitourinary malignancies
Ignacio Duran, MD
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®Emerging immunotherapy combination strategies in genitourinary malignancies
Sandy Srinivas, MD
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Ignacio Duran, MD
Wenxin Xu, MD
Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Jyoti Patel, MD
- MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
- advertisement
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®Treatment Intensification in HR+/HER2- EBC: Who and When?
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®Recent updates from adjuvant trials in HR+/HER2- EBC
Nadia Harbeck, MD, PhD
